Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Colorcon
Express Scripts
Medtronic
Dow

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021395

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

NDA 021395 describes SPIRIVA, which is a drug marketed by Boehringer Ingelheim and is included in two NDAs. It is available from two suppliers. There are twenty patents protecting this drug and one Paragraph IV challenge. Additional details are available on the SPIRIVA profile page.

The generic ingredient in SPIRIVA is tiotropium bromide. There are eight drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the tiotropium bromide profile page.
Summary for 021395
Tradename:SPIRIVA
Applicant:Boehringer Ingelheim
Ingredient:tiotropium bromide
Patents:9
Pharmacology for NDA: 021395
Mechanism of ActionCholinergic Antagonists
Medical Subject Heading (MeSH) Categories for 021395
Suppliers and Packaging for NDA: 021395
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SPIRIVA tiotropium bromide POWDER;INHALATION 021395 NDA Boehringer Ingelheim Pharmaceuticals, Inc. 0597-0075 0597-0075-41 3 BLISTER PACK in 1 CARTON (0597-0075-41) > 10 CAPSULE in 1 BLISTER PACK
SPIRIVA tiotropium bromide POWDER;INHALATION 021395 NDA Boehringer Ingelheim Pharmaceuticals, Inc. 0597-0075 0597-0075-47 9 BLISTER PACK in 1 CARTON (0597-0075-47) > 10 CAPSULE in 1 BLISTER PACK
Paragraph IV (Patent) Challenges for 021395
Tradename Dosage Ingredient NDA Submissiondate
SPIRIVA POWDER;INHALATION tiotropium bromide 021395 2018-05-11

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;INHALATIONStrengthEQ 0.018MG BASE/INH
Approval Date:Jan 30, 2004TE:RLD:Yes
Patent:  Start TrialPatent Expiration:Mar 24, 2022Product Flag?Substance Flag?Delist Request?Y
Patent:  Start TrialPatent Expiration:Mar 24, 2022Product Flag?Substance Flag?Delist Request?Y
Patent:  Start TrialPatent Expiration:Jul 22, 2022Product Flag?Substance Flag?Delist Request?Y

Expired US Patents for NDA 021395

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim SPIRIVA tiotropium bromide POWDER;INHALATION 021395-001 Jan 30, 2004   Start Trial   Start Trial
Boehringer Ingelheim SPIRIVA tiotropium bromide POWDER;INHALATION 021395-001 Jan 30, 2004   Start Trial   Start Trial
Boehringer Ingelheim SPIRIVA tiotropium bromide POWDER;INHALATION 021395-001 Jan 30, 2004   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Moodys
Merck
Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.